Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Two Doses of RP-G28 in Subjects With Lactose Intolerance

Trial Profile

A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Two Doses of RP-G28 in Subjects With Lactose Intolerance

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 06 Nov 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RP G28 (Primary)
  • Indications Lactose intolerance
  • Focus Therapeutic Use
  • Sponsors Ritter Pharmaceuticals
  • Most Recent Events

    • 10 Oct 2018 Results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2018
    • 09 Oct 2018 According to a a Ritter Pharmaceuticals media release, additional phase 2b data showing adaptation of the gut microbiome in lactose intolerance patients, presented at the Annual Scientific Meeting of the American College of Gastroenterology in Philadelphia, Penn.
    • 09 Oct 2018 Additional phase 2b data showing adaptation of the gut microbiome in lactose intolerance patients, presented in a Ritter Pharmaceuticals media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top